Experimental hepatitis b drug shows promise in early trial
NCT ID NCT02452528
First seen Nov 03, 2025 · Last updated May 15, 2026 · Updated 24 times
Summary
This study tested an experimental drug called ARC-520, given alongside standard hepatitis B medications (entecavir or tenofovir), in people with chronic hepatitis B. The goal was to see if it could lower the amount of hepatitis B surface antigen in the blood. Only 4 people took part before the study was stopped early.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site 1
San Francisco, California, 94118, United States
-
Research Site 2
Miami, Florida, 33136, United States
-
Research Site 4
New York, New York, 10029, United States
-
Research Site 6
San Antonio, Texas, 78215, United States
Conditions
Explore the condition pages connected to this study.